Conference Call Summary, page-294

People should also know that the Bronchiolitis trials made the FDA 75% PPA and NPA cut, so that alone qualifies for FDA application. Mr Keating wants to look at the case by case studies first.

Reading the announcement again, interference and background noise can be adjusted without significant changes IMO.

What is a bit ridiculous is having more than one individual coughing plus diagnosing on 'treated' patients.

I mean far out; might as well have a bunch of 1000 patients cough at the same time and have resapp detect the number of patients with respiratory disease.

The trials were highly skewed IMO.

Alot of people got burnt which I feel for them but read between the lines.

If the Australian trials maintain previous detection percentages; this will climb back slowly with confidence.

At the moment RAP is being played by DT unfortunately.